Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial.

J Atheroscler Thromb · 2021 · PMC7957026 · PMID 32493881

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

In the ProFESS trial, clopidogrel monotherapy appeared to show a nonsignificant trend toward stroke prevention compared with the combination of aspirin and dipyridamole in patients with large-artery atherosclerosis (9.4% vs 10.6%) 10 ) .

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.